Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 4/20 | 0.38 |
| ▸ | GBA1 | P04062 | 11/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23696408 | 0.91 | ADRB2 (0.40) | GLSGBA1MAPTADRB2ADRB1 | |
| SCHEMBL25477544 | 0.86 | GLS (0.39) | GLSGBA1ADRB2ADRB1 | |
| SCHEMBL21992355 | 0.81 | MAPT (0.39) | GLSGBA1MAPT | |
| SCHEMBL23945848 | 0.80 | GBA1 (0.44) | GLSGBA1MAPT | |
| SCHEMBL26401475 | 0.77 | ADRB2 (0.42) | GLSGBA1ADRB2ADRB1 | |
| SCHEMBL22861721 | 0.76 | GLS (0.46) | GLSGBA1ADRB2ADRB1 | |
| SCHEMBL21106552 | 0.76 | ADRB2 (0.44) | GLSGBA1ADRB2ADRB1 | |
| SCHEMBL16576128 | 0.74 | FNTA (0.36) | MAPT | |
| SCHEMBL25446872 | 0.73 | GLS (0.37) | GLSGBA1 | |
| SCHEMBL23568346 | 0.72 | GLS (0.41) | GLSGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GLS 4492/4885GBA1 3212/4885GSK3B 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.